Skip to main content
. 2022 Oct 17;13:1032403. doi: 10.3389/fimmu.2022.1032403

Figure 2.

Figure 2

GD2 sugar moiety (A) and correlation of anti-GD2 mAb affinity with clinical efficacy (B) of the GD2 CARTs.